WN
TRIB

Williams & Novak’s Trinity Biotech TRIB Stock Holding History

Williams & Novak’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.6K Buy
4,685
+1,097
+31% +$20.3K 0.04% 136
2026
Q1 		$64.4K Buy
3,588
+478
+15% +$10.6K 0.05% 124
2025
Q4 		$73.8K Buy
3,110
+2,710
+678% +$79.9K 0.06% 127
2025
Q3 		$12.5K Sell
400
-333
-45% -$10.5K 0.01% 139
2025
Q2 		$14.3K Buy
733
+126
+21% +$2.53K 0.01% 133
2025
Q1 		$10.4K Buy
+607
New +$14.4K 0.01% 126
2024
Q1 		– Sell
-67
Closed -$4.29K – 89
2023
Q4 		$4.29K Buy
+67
New +$4.8K ﹤0.01% 91

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Williams & Novak's TRIB Position: Q2 2026 in Review

Williams & Novak increased its Trinity Biotech (TRIB) stake by 31% in Q2 2026, buying an estimated $20.3K and bringing the position to 4,685 shares worth $54.6K. The position accounts for 0.04% of the portfolio, ranked #136.

Williams & Novak first reported a position in TRIB in Q4 2023 and has held it in 7 quarters since. The position peaked at $73.8K in Q4 2025. 8 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

  • Williams & Novak held 4,685 shares of Trinity Biotech worth $54.6K as of Q2 2026.
  • Williams & Novak bought 1,097 Trinity Biotech shares in Q2 2026, an estimated $20.3K.
  • Trinity Biotech made up 0.04% of Williams & Novak's portfolio in Q2 2026, its #136 holding.
  • Williams & Novak first reported a position in Trinity Biotech in Q4 2023 and has held it in 7 quarters since.
  • Williams & Novak's Trinity Biotech position peaked at $73.8K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on Williams & Novak's 13F filing for Q2 2026, filed 8 Jul 2026.